Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Obesity

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Decoding of amidated aromatic C-terminus and sulfation by cholecystokinin receptors reveals conserved and divergent evolutionary mechanisms.

The Journal of biological chemistry·2026

Same author

Identification and functional validation of SPON2 as a novel biomarker for the diagnosis and prognosis in hepatocellular carcinoma.

Journal of gastrointestinal oncology·2026

Same author

Identification and prognostic analysis of genes related to CTNNB1 mutations in hepatocellular carcinoma.

Biology direct·2026

Same author

Risk factors for post-ERCP pancreatitis and assessment of stent exchange intervals in children with chronic pancreatitis: a single-center retrospective study.

BMC pediatrics·2026

Same author

Rsk4 Mediates Brain FGF19 Signaling to Constrain Diet-Induced Obesity in Mice.

Diabetes·2026

Same author

Subtype-Specific Prognosis, Recurrence Patterns, and Molecular Features in 148 Chinese Uterine Sarcomas: A Real-World Study.

Cancers·2026

Search research articles

Related Experiment Video

Updated: Sep 18, 2025

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Recent progress in the pharmacotherapy for obesity.

Jiale Lu¹, Pengfei Liu¹, Mengyang Cai¹

¹Institute of Metabolism and Health, Department of Pathophysiology, School of Basic Medical Sciences, Henan University, Kaifeng, Henan, 475004, China; Zhongzhou Laboratory for Integrative Biology, Zhengzhou, Henan, 450046, China.

European Journal of Pharmacology

|June 24, 2025

Summary

This review covers anti-obesity medications (AOMs) for durable weight loss. It highlights current and emerging therapies, addressing challenges for effective obesity management.

Keywords:

AOMs Combinatory therapy GLP-1 receptor agonists Multi-receptor drugs Obesity

More Related Videos

An Acupoint Catgut-embedding Therapy for Treating Obesity

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Control of Eating Behavior Using a Novel Feedback System

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

Related Experiment Videos

Last Updated: Sep 18, 2025

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

An Acupoint Catgut-embedding Therapy for Treating Obesity

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Control of Eating Behavior Using a Novel Feedback System

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

Area of Science:

Endocrinology
Pharmacology
Public Health

Background:

Obesity is a global epidemic with complex neuroendocrine regulation of energy balance.
Traditional weight loss interventions like diet and exercise often lack sustained efficacy.
Significant unmet needs exist in managing obesity and its associated comorbidities.

Purpose of the Study:

To review current anti-obesity medications (AOMs) and their mechanisms.
To explore emerging pharmacotherapies and innovative treatment strategies.
To identify challenges and opportunities in advancing obesity pharmacotherapy.

Main Methods:

Literature review of current and pipeline anti-obesity medications.
Analysis of mechanisms of action, efficacy, and limitations of various AOMs.
Exploration of combinatory therapies and drug repurposing for obesity.

Main Results:

Current AOMs include lipase inhibitors and hormone-based therapies; emerging options involve multi-receptor agonists.
Innovative approaches like combinatory therapies show potential for durable weight loss.
Challenges include safety, tolerability, and equitable access to obesity treatments.

Conclusions:

Advancing anti-obesity pharmacotherapy requires multidisciplinary research and personalized approaches.
Pharmacotherapy holds promise for transforming obesity management and reducing its global burden.
Addressing safety, tolerability, and access is crucial for effective obesity treatment.